Type 2 Diabetes: The Equitable Between Kidney and Body Size
|
|
- Hannah Adelia Hicks
- 3 years ago
- Views:
Transcription
1 Diabetic Autoimmune Markers in Children and Adolescents With Type 2 Diabetes Eba H. Hathout, MD; Wendy Thomas; Mohamed El-Shahawy, MD, MHA; Fadi Nahab; and John W. Mace, MD ABSTRACT. Background. There is an increase in the incidence of type 2 diabetes in children and adolescents. Absence of known diabetes autoimmune markers is sometimes required to confirm the diagnosis. Objective. To identify clinical and autoimmune characteristics of type 2 diabetes in a pediatric population. Method. We report an analysis of 48 children and adolescents with type 2 diabetes, compared with 39 randomly selected children with type 1 diabetes, diagnosed and followed at the Loma Linda University Pediatric Diabetes Center. Ethnic, familial, seasonal, and autoimmune marker characteristics are outlined. To determine the reliability of antibody testing in confirming the type of diabetes at diagnosis, we studied the incidence of positive islet cell antibodies (ICAs), glutamic acid decarboxylase antibodies (GADs), and insulin autoantibodies (IAAs) at diagnosis in both groups. ICA512, GADs, and IAAs were measured by radioimmunoassay. Results. The cohort with type 2 diabetes had a similar gender distribution as the group with type 1 diabetes but a significantly higher age at diagnosis. Ethnic background was significantly different between the 2 groups, predominantly Hispanic in type 2 and white in type 1. Body mass index was significantly higher in type 2 diabetes (mean kg/m 2 ). Among the patients with type 2 diabetes, 33% presented in diabetic ketoacidosis, random blood glucose at diagnosis ranged from 11.4 to mmol/l ( mg/dl), fasting C-peptide levels ranged from 0.89 to 2.7 nmol/l ( ng/ml; normal: <1.36 nmol/l), and hemoglobin A 1C was % (normal: <6.6%). None of these parameters was significantly different from the type 1 diabetes group. Although the incidence of diabetes antibody markers was significantly lower in type 2 versus type 1 diabetes, 8.1% of patients with type 2 diabetes had positive ICAs, 30.3% had positive GADs, and 34.8% had positive IAAs without ever being treated with insulin. In the type 2 diabetes group, none of the Hispanic patients had ICAs. However, there was no significant correlation between any of the diabetes antibodies and obesity, presence of acanthosis nigricans, or family history of diabetes. The frequency of thyroid antibodies was not significantly different from the group with type 1 diabetes. Daily insulin requirements 1 year after diagnosis were significantly lower in type 2 diabetes, ranging from 0 to 1.2 U/kg with a mean of From the Pediatric Diabetes Center, Loma Linda University Children s Hospital, Loma Linda, California. Received for publication Nov 9, 2000; accepted Jan 29, Reprint requests to (E.H.H.) Pediatric Diabetes Center, Loma Linda University Children s Hospital, Campus St, Coleman Pavilion A1120R, Loma Linda, CA hathout@aol.com PEDIATRICS (ISSN ). Copyright 2001 by the American Academy of Pediatrics. Conclusion. Absence of diabetes autoimmune markers is not a prerequisite for the diagnosis of type 2 diabetes in children and adolescents. Pediatrics 2001;107(6). URL: e102; type 2 diabetes, adolescents, autoimmunity, islet cell antibodies, glutamic acid decarboxylase antibodies. ABBREVIATIONS. ICA, islet cell antibody; GAD, glutamic acid decarboxylase antibody; IAA, insulin autoantibody; BMI, body mass index; DKA, diabetic ketoacidosis; TGA, thyroglobulin antibody; TPOA, thyroid peroxidase antibody; SD, standard deviation. There has been a dramatic increase in the incidence of type 2 diabetes in children and adolescents during the past decade. 1 The disproportionately higher prevalence of type 2 diabetes in minority youth in North America has been highlighted in many recent conferences and publications. 2 The diagnosis has relied primarily on the clinical criteria of hyperglycemia and the presence of 1 or more of the following: belonging to a high-risk minority population, eg, Mexican American; type 2 diabetes in 1 or both parents; obesity; and signs of insulin resistance, such as acanthosis nigricans. 3 Biochemical evidence of endogenous insulin production via basal or stimulated C-peptide levels is sometimes used to confirm the diagnosis. 4 Presence of any of the -cell autoimmune markers, islet cell antibodies (ICAs), glutamic acid decarboxylase antibodies (GADs), or insulin autoantibodies (IAAs) was often used to negate or challenge the diagnosis of type 2 diabetes in children and adolescents. 3,4 However, there are several reports in the adult literature describing and analyzing the incidence of diabetes autoimmune markers in type 2 diabetes in adults The objective of the present study was to outline the ethnic, familial, seasonal, and autoimmune marker characteristics of children and adolescents with type 2 diabetes at the Pediatric Diabetes Center of Loma Linda University. METHODS The number of patients with type 2 diabetes actively followed at the Pediatric Diabetes Center of Loma Linda University Children s Hospital at the time of the study was 48. Diagnosis of type 2 diabetes was based on the revised American Diabetes Association criteria 12 of repeated fasting hyperglycemia (plasma glucose: 7 mmol/l; 126 mg/dl) or casual hyperglycemia (plasma glucose: 11.1 mmol/l; 200 mg/dl) in the presence of polyuria, polydipsia, and unexplained weight loss. The diagnosis was further supported by the presence of 2 or more of the following PEDIATRICS Vol. 107 No. 6 June of4
2 factors: Hispanic, Pacific Island or African, native or Asian-American ancestry, history of type 2 diabetes in a first-degree relative, obesity (body mass index [BMI]: 24 kg/m 2 ), and presence of acanthosis nigricans. Evidence of endogenous insulin production by measuring basal and stimulated C-peptide levels in the nonketotic state was used to confirm the diagnosis. 4 Patients with suspected or genetically documented maturity-onset diabetes of the young or iatrogenic diabetes were given their respective diagnoses. The control group of 39 patients was selected at random (every 10th name in the database given a diagnosis of type 1 diabetes with age of onset of 3 years and current follow-up at Pediatric Diabetes Center of Loma Linda University Children s Hospital). All patient histories were obtained by members of the Pediatric Diabetes Center at the initial clinic visit. Clinical information was obtained retrospectively by hospital and clinic record review. Demographic characteristics examined in this study include age at diagnosis, gender, ethnic background, rank among siblings, household size at diagnosis, season of diagnosis, and family history of diabetes of either type. Past medical history also includes mode of delivery and parental ages at birth. Clinical characteristics at the time of diagnosis include symptoms of a viral illness, such as rhinorrhea or cough, BMI, presence of acanthosis nigricans, blood glucose, hemoglobin A 1C and C-peptide levels, insulin treatment, and presence of diabetic ketoacidosis (DKA). IAAs were measured by I 125 binding capacity (normal: 5 U/mL), GAD65 (GAA), and ICA512 were measured by radioimmunoprecipitation assay (normal: 1 U/mL; Endocrine Sciences Laboratories, Calabassus, CA). Thyroglobulin antibodies (TGAs) and thyroid peroxidase antibodies (TPOAs) were measured by immunochemiluminometric assay (Quest Diagnostics at Nichols Institute, San Juan Capistrano, CA). Data were analyzed in a cross-sectional manner. All data for this study were extracted from pediatric diabetes center charts, which include hospital admission information, onto a structured database form. Data were subsequently entered using Excel, Version 5.0 (Microsoft Co, Seattle, WA), verified by inspection, and checked for erroneous values. Statistical Analysis Continuous data were analyzed using Student s 2-tailed t test. Analysis of categorical variables was accomplished using the 2 test. P values.05 were assigned statistical significance. All P values are 2-tailed. Age, BMI, hemoglobin A 1C, blood glucose, and C-peptide data are presented as mean values standard deviation (SD). RESULTS Age range at diagnosis was 9.7 to 17.9 years for the group with type 2 diabetes and 3.75 to 17 years for the group with type 1 diabetes (Table 1). Ethnic breakdown in type 1 diabetes was similar to that of the background population in distinction to the group with type 2 diabetes, which proportionately consisted of significantly more Hispanics (P.001) and fewer whites (P.011). No particular gender predominance was apparent in either group. There was no significant difference in the ranking of the participants in the family or household size at diagnosis between the 2 groups. Fall was the most common season for diagnosis of type 2 diabetes, compared with winter, which was the predominant season of presentation for the type 1 group (P.01). There was a significantly higher frequency of type 2 diabetes in first-degree relatives of patients with type 2 diabetes (P.001). Past medical history did not show a significant difference in the frequency of birth by cesarean section or parental ages at birth between the 2 groups. BMI at diagnosis of type 2 diabetes ranged from to kg/m 2 (Table 2). This range was significantly higher than BMI at diagnosis of type 1 TABLE 1. Demographic Characteristics of Pediatric Patients With Type 2 Diabetes, Compared With a Group With Type 1 Diabetes Type 2 n 48 Type 1 n 39 P Value* Age in years at diagnosis (mean SD) Current age Gender Males (n 43) Females (n 44) Race Hispanic 62.9% 27.3%.001 White 20.0% 51.5%.011 Black 8.6% 12.1%.689 Asian 2.9% 3.0% First born or only child 36.7% 41.2%.712 Number in household at diagnosis Diagnosed in fall 32.5% 11.1%.01 Diagnosed in spring 30.0% 13.9% Diagnosed in winter 22.5% 50% Diagnosed in summer 15.0% 25% Family history of diabetes Type % 0.0%.001 in first-degree relative Type % 76.5%.684 in second-degree relative Type 1 2.8% 5.9%.522 in first-degree relative Type 1 in second-degree relative 2.8% 23.5%.010 * 2 for categorical variables, t test for continuous variables. TABLE 2. Clinical and Autoimmune Marker Characteristics of Patients With Type 2 Diabetes Variable Type 2 Type 1 P Value* Symptoms of viral illness 14.3% 29.2%.074 at diagnosis BMI (kg/m 2 ) Acanthosis nigricans 37% 0 On insulin at diagnosis 68.6% 100%.045 DKA at diagnosis 33.3% 53.3%.142 Hemoglobin A 1C at diagnosis (% SD) Blood glucose at diagnosis C-peptide at diagnosis Positive ICA 8.1% 71.1%.001 Positive GAD 30.3% 75.7%.001 Positive IAA 34.8% 76.5%.009 Positive TPOA 20.0% 8.8%.187 Positive TGA 14.3% 10.5%.625 Insulin-requiring 1 y after diagnosis 50% 100% for categorical variables, t test for continuous variables. diabetes patients (range: ; P.0001). Acanthosis nigricans was exclusive to type 2 diabetes, occurring in 37% of patients in that group. The percentage of patients with type 2 diabetes initially treated with insulin was 68.6%. The rest were managed with a combination of diet and exercise, with or without metformin. Although blood glucose, hemoglobin A 1C levels, and the percentage of patients presenting in DKA were all lower in type 2 (vs type 1) diabetes, their difference between the 2 groups was not statistically significant. Among patients with type 2 diabetes, 30.3% had 2of4 AUTOIMMUNITY IN PEDIATRIC TYPE 2 DIABETES
3 positive GADs ( 1.0 U/mL), 34.8% had positive IAAs ( 5 U/mL), and 8.1% had positive ICAs ( 1.0 U/mL; Table 2). Positive ICAs were inversely correlated with Hispanic ancestry. Otherwise, there was no significant correlation among any of the 3 antibodies and race or presence of obesity, acanthosis, or a family history of diabetes of either type. ICA and GAD frequencies in type 2 patients were significantly lower than in type 1 diabetes patients (positive frequency range: 71% 76%; P.01). However, the frequency of positive TGAs and TPOAs was not significantly different between the 2 groups. Subsequent clinical correlation showed that 3 of the type 2 diabetes patients with positive thyroid antibodies had concomitant hypothyroidism at the time of the study, whereas none of the type 1 group had evidence thereof. Treatment initiation and modification decisions for patients with type 2 diabetes in this study were made by 2 pediatric endocrinologists. One year after diagnosis, 50% of patients with type 2 diabetes were not on insulin therapy and were controlled with diet and exercise alone or in combination with metformin. Retrospective analysis showed that 47% of these patients had a first-degree relative with type 2 diabetes, 36% had acanthosis nigricans, 89% had BMI 24 kg/m 2, and 27% had DKA at diagnosis. In addition, 18.75% of these patients had positive GADs (Table 3), 37.5% had positive IAAs, and 0.0% had positive ICAs. The majority of patients with type 2 diabetes not requiring insulin 1 year after diagnosis remained off insulin up to the time of the present review, conducted 3 to 5 years after their diagnosis. The remaining patients were either diagnosed within 2 years of this review or lost to follow-up. Addition of, or transition to, insulin therapy was based on lack of glycemic improvement (hemoglobin A 1C remains or rises to 8%) despite maximal attempts at diet and exercise and a trial of metformin up to 2 g per day. In patients treated with insulin 1 year after diagnosis, weight-adjusted daily insulin requirements were significantly lower than in patients with type 1 diabetes (P.025), ranging from 0 to 1.2 U/kg with a mean of All type 2 patients with positive ICA titers were on insulin therapy 1 year after diagnosis. TABLE 3. Diabetes Autoimmune Markers in Noninsulin- Requiring Patients With Type 2 Diabetes Percentage With Positive Titer Percentage With Negative Titer GAD IAA ICA DISCUSSION Type 2 diabetes in children and adolescents underwent a 10-fold increase over the past decade. 12,14 This increase has been primarily attributed to a problem of childhood obesity, which has reached epidemic proportions. 15 Genetic, ethnic, and environmental risk factors have also been considered. 3 This, together with a potentially long asymptomatic period for type 2 diabetes, raise serious concerns for long-term microvascular and macrovascular complications. Demographic characteristics of adolescents with type 2 diabetes in our study are similar to those reported previously by others in terms of predominance of Hispanic (Mexican American) ancestry, and association with obesity, acanthosis nigricans, and family history. However, given that the ethnic breakdown in our control group was similar to that of the background population, our study did not show the significantly higher incidence of type 2 diabetes in black adolescents described by others. 14,16 Of interest is the 1 patient with type 2 diabetes with a family history of type 1 diabetes in a first-degree relative. That patient is a black female, diagnosed at 13 years old, with BMI of 41.6 kg/m 2, significant acanthosis, normal C-peptide, and negative diabetes and thyroid antibodies. Verification of the presumed type 1 diabetes in that relative was not possible. The increase in BMI in type 2 versus type 1 diabetes might have been exaggerated by the fact that all our patients with type 2 diabetes were pubertal at the time of the study. The trend shown in this study for type 2 diabetes to be diagnosed in the fall might be the consequence of the summer vacation, a period of relative excess eating and decreased activity for many adolescents. In contrast, it might have been a coincidental finding brought to medical attention by requirements of a school physical examination. The diagnosis of type 2 diabetes relies heavily on clinical criteria, such as Hispanic or black ancestry, positive family history, obesity, evidence of insulin resistance, and absent or milder-than-expected plasma glucose fluctuations, ketosis, or hypoglycemic reactions to insulin. Measurable fasting or stimulated C-peptide levels, reflecting endogenous pancreatic insulin secretion, are not exclusively diagnostic of type 2 diabetes, because they can theoretically be present in the honeymoon phase of type 1 diabetes. However, absence of -cell autoimmune markers (ICA, GAD, and IAA without previous insulin therapy) has been a diagnostic prerequisite for type 2 diabetes in most pediatric cases, particularly pertaining to trials of noninsulin therapeutic modalities. Evidence of -cell autoimmunity in adults with type 2 diabetes, however, has been well documented in the literature. GAD positivity has been reported in 3.8% to 16.1% of patients with type 2 diabetes ICA prevalence in type 2 diabetes was reported as 1.6% in 1 study 5 and 4.8% in another. 11 Moreover, some reports suggested that ICA positivity in type 2 diabetes predicted future insulin requirement 17,18 and that GAD positivity correlated with a younger age of diagnosis, lower C-peptide at diagnosis, and increased probability of insulin requirement. 6,7,19 No differences in BMI or serum C-peptide levels could be found between GAD-positive and GAD-negative type 2 patients at diagnosis. 10 Of interest is 1 study showing that fasting C-peptide levels in ICA-positive patients with type 2 diabetes were similar to patients with type 1 diabetes, 3 years after diagnosis. 20 In the present study, the higher incidence of -cell 3of4
4 antibodies in adolescents with type 2 diabetes (Table 2) supports the previously reported correlation of positive diabetes antibodies with younger age at diagnosis. 8 Our data also suggest that ICA antibody positivity at diagnosis could be a predictor of future insulin need. 17,18 The possibility that positive diabetes antibodies in adolescents with noninsulin-requiring diabetes may represent a form of early-onset latent autoimmune diabetes similar to that described in adults (latent autoimmune diabetes in adults) 21,22 needs to be considered. This form of diabetes, however, was not reported to be specifically associated with obesity or Hispanic ancestry. Long-term data on insulin requirements can shed more light on this area. There is also the possibility that some type 2 patients, particularly those requiring insulin, are actually obese patients with type 1 diabetes. Studying genetic determinants specific to either type of diabetes, eg, human leukocyte antigen-dq/dr subtypes, might be needed in the future for typing of diabetes in such patients. 23 The fact that autoimmunity should not exclude the possibility of type 2 diabetes in adolescents is supported by the presence of positive thyroid (TPOA and TGA) antibodies and hypothyroidism in type 2 patients, which was detected in 3 patients in this series. Because the focus of this study was the typing (and not the diagnosis) of diabetes in children, antibody levels in healthy controls were not included. Data regarding insulin treatment in type 2 adolescents, particularly at the time of diagnosis, should be interpreted with caution. Many patients had been misdiagnosed as having type 1 diabetes based on either age or DKA at presentation. In addition, lack of a Food and Drug Administration-approved stepwise approach to the treatment of type 2 diabetes in children often facilitated the use of insulin as initial therapy. Moreover, social and cultural factors interfering with compliance with noninsulin regimens, particularly in the adolescent age group, frequently lead to use of insulin in noninsulin-requiring patients. Another entity not addressed in this study consists of patients who are both insulin-deficient and insulin-resistant. 24 This is exemplified by obese type 1 adolescent patients, with onset of diabetes in early childhood, evidence of compliance in a supervised setting, and daily insulin requirements exceeding 2 U/kg. Whether those patients, who have both types of diabetes, could be categorized and treated as such merits additional exploration. The above data reflect the broad spectrum of pancreatic and peripheral abnormalities that could lead to adolescent diabetes. Our study and many studies in the adult literature suggest that the presence of diabetes autoimmune markers should not be used to exclude the diagnosis of type 2 diabetes in children and adolescents. Larger prospective pediatric diabetes studies are needed to confirm the validity of this conclusion. Acceptance of this concept in scientific and research settings could open the door to trials of a broader range of therapeutic modalities for a group of children and adolescents who were previously labeled insulin-dependent for life. REFERENCES 1. Rosenbloom AL. Emerging epidemic of type 2 diabetes in Mexican- American youth. Diabetes Care. 1999;22: Young RS, Rosenbloom AL. Type 2 (non-insulin dependent) diabetes in minority youth: conference report. Clin Pediatr. 1998;37: Glaser NS, Jones KL. Non-insulin dependent diabetes mellitus in Mexican-American children. West J Med. 1998;168: Clemons RD, Gottschalk ME, Jones KL. Basal and postprandial C- peptide values in a racially mixed population of adolescents with type 2 diabetes mellitus. Diabetes. 1999;48(suppl 1): Niskanen LK, Tuomi T, Karjalainen J, et al. GAD antibodies in NIDDM: ten-year follow-up from the diagnosis. Diabetes Care. 1995;18: Abiru N, Takino H, Yano M, et al. Clinical evaluation of non-insulin dependent diabetes mellitus patients with autoantibodies to glutamic acid decarboxylase. J Autoimmun. 1996;9: Inukai T, Fujiwara Y, Tayama K, et al. Clinical characteristics of patients with the initial diagnosis of NIDDM with positivity for antibodies to glutamic acid decarboxylase. Exp Clin Endocrinol Diabetes. 1997;105: Tuomi T, Carlsson A, Li H, et al. Clinical and genetical characteristics of type 2 diabetes with and without antibodies. Diabetes. 1999;48: Tsuruoka A, Matsuba I, Toyota T, et al. Antibodies to GAD in Japanese diabetic patients: a multicenter study. Diabetes Res Clin Pract. 1995;28: Maruyama T, Kasuga A, Ozawa Y, et al. Glutamic acid decarboxylase 65 (GAD65) antibodies and insulin auto-antibodies in Japanese patients with non-insulin-dependent diabetes mellitus. Endocr J. 1997;44: Thai AC, Ng WY, Loke KY, et al. Anti-GAD antibodies in Chinese patients with youth and adult onset IDDM and NIDDM. Diabetologia. 1997;40: The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Committee report. Diabetes Care. 2000;23(suppl 1) 13. Pinhas-Hamiel O, Zeitler P. A weighty problem: diagnosis and treatment of type 2 diabetes in adolescents. Diabetes Spectrum. 1997;10: Fagot-Campagna A. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr. 2000;136: Young TK. Childhood obesity in a population at high risk for type 2 diabetes. J Pediatr. 2000;136: Danadian K. Insulin sensitivity in African-American children with and without family history of type 2 diabetes. Diabetes Care. 1999;22: DiMario U, Irvine WJ, Borsey DQ, et al. Immune abnormalities in diabetic patients not requiring insulin at diagnosis. Diabetologia. 1983; 25: Littorin B, Sundkvist G, Hagopian W, et al. Islet cell and glutamic acid decaroxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment: a cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes. Diabetes Care. 1999;22: Kasuga A, Maruyama T, Ozawa Y, et al. Antibody to the M(r) 65,000 isoform of glutamic acid decarboxylase detected in non-insulindependent diabetes in Japanese. J Autoimmun. 1996;9: Gottsater A, Landin-Olsson M, Fernlund P, et al. Beta-cell function in relation to islet cell antibodies during the first 3 year after clinical diagnosis of diabetes in type 2 diabetic patients. Diabetes Care. 1993;16: Elbein SC, Wegner K, Miles C, Yu L, Eisenbarth G. The role of late-onset autoimmune diabetes in white familial NIDDM pedigrees. Diabetes Care. 1997;20: Schranz DB, Berkis L, Landin-Olsson M, et al. Newly diagnosed latent autoimmune diabetes in adults (LADA) is associated with low level glutamate decarboxylase (GAD65) and IA-2 autoantibodies: diabetes incidence study in Sweden (DISS). Horm Metab Res. 2000;32: Tiberti C, Buzzetti R, Anastasi E, et al. Autoantibody negative new onset type 1 diabetic patients lacking high risk HLA alleles in a Caucasian population: are these type 1b diabetes cases? Diabetes Metab Res Rev. 2000;16: Witchel SF, Arslanian S. Ovarian responses to hcg stimulation: insulin resistance/hyperinsulinemia vs insulin deficiency. Clin Endocrinol (Oxf). 1999;51: of4 AUTOIMMUNITY IN PEDIATRIC TYPE 2 DIABETES
5 Diabetic Autoimmune Markers in Children and Adolescents With Type 2 Diabetes Eba H. Hathout, Wendy Thomas, Mohamed El-Shahawy, Fadi Nahab and John W. Mace Pediatrics 2001;107;e102 DOI: /peds e102 Updated Information & Services References Citations Post-Publication Peer Reviews (P 3 Rs) Subspecialty Collections Permissions & Licensing Reprints including high resolution figures, can be found at: /content/107/6/e102.full.html This article cites 23 articles, 8 of which can be accessed free at: /content/107/6/e102.full.html#ref-list-1 This article has been cited by 1 HighWire-hosted articles: /content/107/6/e102.full.html#related-urls 2 P 3 Rs have been posted to this article /cgi/eletters/107/6/e102 This article, along with others on similar topics, appears in the following collection(s): Endocrinology /cgi/collection/endocrinology_sub Diabetes Mellitus /cgi/collection/diabetes_mellitus_sub Metabolic Disorders /cgi/collection/metabolic_disorders_sub Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: /site/misc/permissions.xhtml Information about ordering reprints can be found online: /site/misc/reprints.xhtml PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, Copyright 2001 by the American Academy of Pediatrics. All rights reserved. Print ISSN: Online ISSN:
6 Diabetic Autoimmune Markers in Children and Adolescents With Type 2 Diabetes Eba H. Hathout, Wendy Thomas, Mohamed El-Shahawy, Fadi Nahab and John W. Mace Pediatrics 2001;107;e102 DOI: /peds e102 The online version of this article, along with updated information and services, is located on the World Wide Web at: /content/107/6/e102.full.html PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, Copyright 2001 by the American Academy of Pediatrics. All rights reserved. Print ISSN: Online ISSN:
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationThe nomenclature. Latent autoimmune diabetes of adulthood: classifying type 1.5 diabetes mellitus
Latent autoimmune diabetes of adulthood: classifying type 1.5 diabetes mellitus Jay H. Shubrook Jr, DO The nomenclature for diabetes mellitus has changed during the past 40 years. In the 1970s, age was
More informationDiagnosis, classification and prevention of diabetes
Diagnosis, classification and prevention of diabetes Section 1 1 of 4 Curriculum Module II 1 Diagnosis, classification and presentation of diabetes Slide 2 of 48 Polyurea Definition of diabetes Slide 3
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationDouble Diabetes: Definition, Diagnosis, Treatment, Prediction and Prevention.
Double Diabetes: Definition, Diagnosis, Treatment, Prediction and Prevention. Professor Paolo Pozzilli University Campus Bio-Medico, Rome Institute of Cell & Molecular Science, Queen Mary, University of
More informationType 2 Diabetes Mellitus in Overweight and Obese Children
JKAU: Type Med. 2 Diabetes Sci., Vol. Mellitus 12, pp: in 97-106 Overweight ( 2005 and A.D. Obese / 1425-1426 Children A.H.) 97 Type 2 Diabetes Mellitus in Overweight and Obese Children ABDULRAHMAN A.
More informationUnraveling non-type 1 diabetes mellitus in childhood
Unraveling non-type 1 diabetes mellitus in childhood Shazhan Amed, MD, The Hospital for Sick Children Heather Dean, MD, Winnipeg Children s Hospital Jill Hamilton, MD, The Hospital for Sick Children Recently,
More informationTreatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections.
National Diabetes Statistics What is diabetes? Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both.
More informationDR. Trinh Thi Kim Hue
TYPE 2 DIABETES IN THE CHILD AND ADOLESCENT DR. Trinh Thi Kim Hue CONTENTS Definition Diagnosis Treatment Comorbidities and Complications Comorbidities and Complications Screening for T2D References DEFINITION
More informationDiabetes is a chronic disease that affects people
Reimbursement for Pediatric Diabetes Intensive Case Management: A Model for Chronic Diseases? Joni K. Beck, PharmD, CDE*; Kathy J. Logan, RN, MS, RD/LD, CDE*; Robert M. Hamm, PhD*; Scott M. Sproat, MHA
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationKansas Behavioral Health Risk Bulletin
Kansas Behavioral Health Risk Bulletin Kansas Department of Health and Environment November 7, 1995 Bureau of Chronic Disease and Health Promotion Vol. 1 No. 12 Diabetes Mellitus in Kansas Diabetes mellitus
More informationDiabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO
Diabetes and Obesity in Children Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO Diabetes and Obesity in Children What is Diabetes? How are Diabetes and Obesity
More informationDiabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
More informationDepartment Of Biochemistry. Subject: Diabetes Mellitus. Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage.
Department Of Biochemistry Subject: Diabetes Mellitus Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage. Diabetes mellitus : Type 1 & Type 2 What is diabestes mellitus?
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationWhat Will Open the Doors for Children and Youth With Special Health Care Needs From Traditionally Underserved Communities?
What Will Open the Doors for Children and Youth With Special Health Care Needs From Traditionally Underserved Communities? The articles in this supplement to Pediatrics raise serious questions about the
More informationChapter 3 Type 1 Diabetes
Chapter 3 Type 1 Diabetes Type 1 diabetes is one of the most common chronic disorders of childhood. Unfortunately, it is increasing in incidence, particularly in young children. The reason for this is
More informationOverview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health
Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.
More information6.4 Diabetes. 6 Priority diseases and reasons for inclusion. Background. Developments since 2004. See Background Paper 6.4 (BP6_4DM.
6 Priority diseases and reasons for inclusion 6.4 Diabetes See Background Paper 6.4 (BP6_4DM.pdf) Background Diabetes and diabetes-related illnesses place an enormous burden on the health care systems
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More information1333 Plaza Blvd, Suite E, Central Point, OR 97502 * www.mountainviewvet.net
1333 Plaza Blvd, Suite E, Central Point, OR 97502 * www.mountainviewvet.net Diabetes Mellitus (in cats) Diabetes, sugar Affected Animals: Most diabetic cats are older than 10 years of age when they are
More informationGayle Curto, RN, BSN, CDE Clinical Coordinator
Gayle Curto, RN, BSN, CDE Clinical Coordinator INTRODUCTION Historical Program Overview Leadership Team Mission Statement Diabetes Center Demographics for 2011 Older Adult Population HISTORICAL PROGRAM
More informationNutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT
1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:
More informationDiabetes epidemics- classification and prevalence Grazyna Sypniewska
Diabetes epidemics- classification and prevalence Grazyna Sypniewska Dept.of Laboratory Medicine, Collegium Medicum N Copernicus University, Bydgoszcz, Poland 14th EFLM Postgraduate Course, Dubrovnik 2014
More informationMANAGEMENT OF TYPE - 1 DIABETES MELLITUS
MANAGEMENT OF TYPE - 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationGlycemic Control of Type 2 Diabetes Mellitus
Bahrain Medical Bulletin, Vol. 28, No. 3, September 2006 Glycemic Control of Type 2 Diabetes Mellitus Majeda Fikree* Baderuldeen Hanafi** Zahra Ali Hussain** Emad M Masuadi*** Objective: To determine the
More informationTraditional View of Diabetes. Are children with type 1 diabetes obese: What can we do? 8/9/2012. Change in Traditional View of Diabetes
Are children with type 1 diabetes obese: What can we do? Traditional View of Diabetes Type 1 Diabetes ( T1DM) Onset Juvenile Lean Type 2 Diabetes ( T2DM) Onset Adult Obese QI Project Indrajit Majumdar
More informationOriginal Research Paper
1 of 6 Original Research Paper Age at diagnosis and family history in Type II diabetes: implications for office screening Ching-Ye Hong MBBS, MCGP, FAFP, FRACGP Kee-Seng Chia MBBS, MSc (OM), MD Ching-Ye
More informationtips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden:
tips Top International Publications Selection Insulin Pump Users Early detection of insulin deprivation in continuous subcutaneous insulin infusion-treated Patients with TD Population Study of Pediatric
More informationPreventing Pediatric Diabetes: Are Racial Disparities A Factor? A Children s Health Fund Issue Brief February 2004
Preventing Pediatric Diabetes: Are Racial Disparities A Factor? A Children s Health Fund Issue Brief February 2004 The Children s Health Fund The Children s Health Fund (CHF), working with hospitals and
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationStatistics of Type 2 Diabetes
Statistics of Type 2 Diabetes Of the 17 million Americans with diabetes, 90 percent to 95 percent have type 2 diabetes. Of these, half are unaware they have the disease. People with type 2 diabetes often
More informationCauses, incidence, and risk factors
Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,
More informationMarkham Stouffville Hospital
Markham Stouffville Hospital Adult Diabetes Education Frequently Asked Questions What is diabetes? Diabetes is a disease in which blood glucose levels are above normal. Most of the food we eat is turned
More informationDiabetes mellitus An overview. Dr.Prasad Katulanda MBBS, MD, Dphil Consultant Endocrinologist/diabetologist Senior Lecturer in Medicine
Diabetes mellitus An overview Dr.Prasad Katulanda MBBS, MD, Dphil Consultant Endocrinologist/diabetologist Senior Lecturer in Medicine ASCEND 2011 Objectives Definition Magnitude of the problem & Epidemiology
More informationA prospective study on drug utilization pattern of anti-diabetic drugs in rural areas of Islampur, India
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (5):33-37 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationCriteria: CWQI HCS-123 (This criteria is consistent with CMS guidelines for External Infusion Insulin Pumps)
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Origination Date: 05/15 Revision Date(s): 05/2015 Developed By: Medical Criteria Committee 06/24/2015 External Infusion Insulin Pumps Page 1 of
More informationUnderstanding the Science of Type 2 Diabetes. Anne Westbrook and April Gardner NABT Dallas, TX November 1, 2012
Understanding the Science of Type 2 Diabetes Anne Westbrook and April Gardner NABT Dallas, TX November 1, 2012 Biological Sciences Curriculum Study (BSCS) Founded in 1958 as a curriculum study Committed
More informationType 2 Diabetes Mellitus and Insulin resistance syndrome in Children
Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children
More informationFamily History and Diabetes. Practical Genomics for the Public Health Professional
Family History and Diabetes Practical Genomics for the Public Health Professional Outline Overview of Type 2 Diabetes/Gestational Diabetes Familial/Genetic Nature of Diabetes Interaction of Genes and Environment
More informationTuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University
Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die
More informationBACKGROUND. ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes
BACKGROUND More than 25% of people with diabetes take insulin ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes Insulin identified as the most effective
More informationDisclosures. Types of Diabetes Mellitus. Type 1 Diabetes Mellitus. Principles of Basal-Bolus Insulin Therapy and Carbohydrate Counting
Principles of Basal-Bolus Insulin Therapy and Carbohydrate Counting Disclosures I do not have any relevant financial relationships with any commercial interests. Henry K. Driscoll, MD, FACP Huntington
More informationCURRENT THERAPEUTIC RESEARCH
CURRENT THERAPEUTIC RESEARCH VOLUME 70, NUMBER I, FEBRUARY 2009 Case Series Adjusting the Basal Insulin Regimen of Patients With Type 1 Diabetes Mellitus Receiving Insulin Pump Therapy During the Ramadan
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationDiabetes: The Numbers
Diabetes: The Numbers Changing the Way Diabetes is Treated. What is Diabetes? Diabetes is a group of diseases characterized by high levels of blood glucose (blood sugar) Diabetes can lead to serious health
More informationConnecticut Diabetes Statistics
Connecticut Diabetes Statistics What is Diabetes? State Public Health Actions (1305, SHAPE) Grant March 2015 Page 1 of 16 Diabetes is a disease in which blood glucose levels are above normal. Blood glucose
More informationType 1 diabetes FACT SHEET 57
Important points Diabetes mellitus (diabetes) is a condition resulting in high levels of sugar (glucose) in the blood There are several types of diabetes: type 1 (insulin dependent diabetes), type 2 (non-insulin
More informationAbdulaziz Al-Subaie. Anfal Al-Shalwi
Abdulaziz Al-Subaie Anfal Al-Shalwi Introduction what is diabetes mellitus? A chronic metabolic disorder characterized by high blood glucose level caused by insulin deficiency and sometimes accompanied
More informationETIOLOGIC CLASSIFICATION. Type I diabetes Type II diabetes
DIABETES MELLITUS DEFINITION It is a common, chronic, metabolic syndrome characterized by hyperglycemia as a cardinal biochemical feature. Resulting from absolute lack of insulin. Abnormal metabolism of
More informationUsing a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes
Special Series: AAFP Award-winning Research Papers Vol. 31, No. 5 331 Using a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes Gary Ruoff, MD; Lynn S. Gray, MD, MPH
More informationProtein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075
Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date
More informationMATERNAL AND CHILD HEALTH BRIEF #2:
MATERNAL AND CHILD HEALTH BRIEF #2: OBESITY AMONG CHILDREN AND ADOLESCENTS SEPTEMBER 2012 OBESITY DEFINED Obesity and overweight are typically measured OVERVIEW in terms of Body Mass Index or BMI. BMI
More informationChildhood Diabetes: Treatment and Prevention Kelly Moore, MD January 2013
Childhood Diabetes: Treatment and Prevention Kelly Moore, MD January 2013 We want to thank everyone else here with the Division of Diabetes Treatment and Prevention including Dr. Wendy Sandoval. I appreciate
More informationSection 5: Type 2 Diabetes
SECTION OVERVIEW Definition and Symptoms Blood Glucose Monitoring Healthy Eating Physical Activity Oral Medication Insulin Sharps Disposal Definition and Symptoms Type 2 diabetes is occurring more frequently
More informationImpact of Diabetes on Treatment Outcomes among Maryland Tuberculosis Cases, 2004-2005. Tania Tang PHASE Symposium May 12, 2007
Impact of Diabetes on Treatment Outcomes among Maryland Tuberculosis Cases, 2004-2005 Tania Tang PHASE Symposium May 12, 2007 Presentation Outline Background Research Questions Methods Results Discussion
More informationCHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications
CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)
More informationHow To Know If You Have Microalbuminuria
3 PREVALENCE AND PREDICTORS OF MICROALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A CROSS-SECTIONAL OBSERVATIONAL STUDY Dr Ashok S Goswami *, Dr Janardan V Bhatt**; Dr Hitesh Patel *** *Associate
More informationGraves disease in childhood Antithyroid drug therapy
83rd Annual Meeting of the ATA October 620, 203 Duration of antithyroid drugs treatment Disclosure Nothing to disclose Pr Juliane Léger Paediatric Endocrinology Department Paris Diderot University Hôpital
More informationDiabetes. African Americans were disproportionately impacted by diabetes. Table 1 Diabetes deaths by race/ethnicity CHRONIC DISEASES
Diabetes African Americans were disproportionately impacted by diabetes. African Americans were most likely to die of diabetes. People living in San Pablo, Pittsburg, Antioch and Richmond were more likely
More informationAm I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes NATIONAL DIABETES INFORMATION CLEARINGHOUSE
NATIONAL DIABETES INFORMATION CLEARINGHOUSE Am I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes U.S. Department of Health and Human Services National Institutes of Health
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationDiabetic Ketoacidosis: When Sugar Isn t Sweet!!!
Diabetic Ketoacidosis: When Sugar Isn t Sweet!!! W Ricks Hanna Jr MD Assistant Professor of Pediatrics University of Tennessee Health Science Center LeBonheur Children s Hospital Introduction Diabetes
More informationNational Diabetes Fact Sheet, 2011
National Diabetes Fact Sheet, 2011 FAST FACTS ON DIABETES Diabetes affects 25.8 million people 8.3% of the U.S. population DIAGNOSED 18.8 million people UNDIAGNOSED 7.0 million people All ages, 2010 Citation
More informationRole of Body Weight Reduction in Obesity-Associated Co-Morbidities
Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:
More informationManagement of Children with newly diagnosed type 1 diabetes (up until their 18th Birthday)
Title: Author: Speciality / Division: Directorate: CLINICAL GUIDELINES ID TAG Management of Children with newly diagnosed type 1 diabetes (up until their 18th Birthday) Dr Teresa Mulroe and Dr Sarinda
More informationIs Insulin Effecting Your Weight Loss and Your Health?
Is Insulin Effecting Your Weight Loss and Your Health? Teressa Alexander, M.D., FACOG Women s Healthcare Associates www.rushcopley.com/whca 630-978-6886 Obesity is Epidemic in the US 2/3rds of U.S. adults
More informationType 1 Diabetes ( Juvenile Diabetes)
Type 1 Diabetes W ( Juvenile Diabetes) hat is Type 1 Diabetes? Type 1 diabetes, also known as juvenile-onset diabetes, is one of the three main forms of diabetes affecting millions of people worldwide.
More informationARE FLORIDA'S CHILDREN BORN HEALTHY AND DO THEY HAVE HEALTH INSURANCE?
infant mortality rate per 1,000 live births ARE FLORIDA'S CHILDREN BORN HEALTHY AND DO THEY HAVE HEALTH INSURANCE? Too Many of Florida's Babies Die at Birth, Particularly African American Infants In the
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationViral Hepatitis Case Report
Page 1 of 9 Viral Hepatitis Case Report Perinatal Hepatitis B Virus Infection Michigan Department of Community Health Communicable Disease Division Investigation Information Investigation ID Onset Date
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationMEDICAL COVERAGE POLICY. SERVICE: Insulin Pump and Continuous Glucose Monitoring. PRIOR AUTHORIZATION: Required. POLICY:
Important note Even though this policy may indicate that a particular service or supply may be considered covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit
More informationDiabetes. Prevalence. in New York State
Adult Diabetes Prevalence in New York State Diabetes Prevention and Control Program Bureau of Chronic Disease Evaluation and Research New York State Department of Health Authors: Bureau of Chronic Disease
More informationTHE AUTOIMMUNE destruction of pancreatic cells
0021-972X/00/$03.00/0 Vol. 85, No. 1 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Autoantibody Recognition of COOH-Terminal Epitopes of GAD65
More informationSeton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
More informationPhil. J. Internal Medicine, 47: 25-30, Jan.-Feb., 2009
Original Articles Pancreatic Insulin Response among Filipino 25 Phil. J. Internal Medicine, 47: 25-3, Jan.-Feb., 29 COMPARISON OF PANCREATIC INSULIN RESPONSE TO GLYCEMIA AMONG FILIPINO SUBJECTS OF VARIOUS
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationCenters for Disease Control and Prevention National Institutes of Health
5 Diabetes Co-Lead Agencies: Centers for Disease Control and Prevention National Institutes of Health Contents Goal...Page 5-3 Overview...Page 5-3 Issues...Page 5-3 Trends...Page 5-4 Disparities...Page
More informationDiabetes Prevention in Latinos
Diabetes Prevention in Latinos Matthew O Brien, MD, MSc Assistant Professor of Medicine and Public Health Northwestern Feinberg School of Medicine Institute for Public Health and Medicine October 17, 2013
More informationEstimates of New HIV Infections in the United States
Estimates of New HIV Infections in the United States Accurately tracking the HIV epidemic is essential to the nation s HIV prevention efforts. Yet monitoring trends in new HIV infections has historically
More informationObstructive sleep apnea and type 2 diabetes Obstructive Sleep Apnea (OSA) may contribute to or exacerbate type 2 diabetes for some of your patients.
Obstructive sleep apnea and type 2 diabetes Obstructive Sleep Apnea (OSA) may contribute to or exacerbate type 2 diabetes for some of your patients. Prevalence of OSA and diabetes Prevalence of OSA Five
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Authors: Dr. M. Love, Kathy Harrigan Reviewers:
More informationORIGINAL ARTICLE INSULIN DEFICIENCY AMONG NEWLY DIAGNOSED TYPE 2 DIABETICS
ORIGINAL ARTICLE INSULIN DEFICIENCY AMONG NEWLY DIAGNOSED TYPE 2 DIABETICS Tahira Naseem, Riffat Yasmin, Naeema Afzal*, Ambreen Farrukh, Rubina Faisal Paul**, Mukhtiar Hassan* Department of Chemical Pathology,
More informationThe Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies
CLINICAL DIABETES VOL. 18 NO. 2 Spring 2000 PRACTICAL POINTERS The Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies Barbara A. Ramlo-Halsted,
More informationPractical Applications of Insulin Pump Therapy in Type 2 Diabetes
Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Wendy Lane, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title. Summary
More informationGUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*
71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the
More informationDistinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationGlucose Tolerance Categories. Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationHEALTH CARE IN the United States is now engaged in a second quality revolution,
SUPPLEMENT ARTICLE Health Information Systems and Physician Quality: Role of the American Board of Pediatrics Maintenance of Certification in Improving Children s Health Care Paul Miles, MD American Board
More informationHOW TO CARE FOR A PATIENT WITH DIABETES
HOW TO CARE FOR A PATIENT WITH DIABETES INTRODUCTION Diabetes is one of the most common diseases in the United States, and diabetes is a disease that affects the way the body handles blood sugar. Approximately
More informationPowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.
PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY 12a FOCUS ON Your Risk for Diabetes Your Risk for Diabetes! Since 1980,Diabetes has increased by 50 %. Diabetes has increased by 70 percent
More informationDiabetes and Obesity. The diabesity epidemic
Diabetes and Obesity Frank B. Diamond, Jr. M.D. Professor of Pediatrics University of South Florida College of Medicine The diabesity epidemic Prevalence of diabetes worldwide was over 135 million people
More informationStarting Insulin Sooner Than Later
Starting Insulin Sooner Than Later Rotorua GP Insulin Seminar 13 June 2014 Kingsley Nirmalaraj MBBS, FRACP, FACE Consultant Endocrinologist and Physician Tauranga Hospital/ Bay Endocrinology Ltd Declaration
More informationInsulin lispro is as effective as regular insulin in optimising metabolic control and preserving b-cell function at onset of type 1 diabetes mellitus
Diabetes Research and Clinical Practice 60 (2003) 153/159 www.elsevier.com/locate/diabres Insulin lispro is as effective as regular insulin in optimising metabolic control and preserving b-cell function
More informationDiabetes in Children and Adolescents
Diabetes in Children and Adolescents Thomas M. Parker, Pharm.D., CDE; and Brian K. Irons, Pharm.D., BCPS, BC-ADM Reviewed by Lisa M. Lubsch, Pharm.D., AE-C; Katherine H. Chessman, Pharm.D., FCCP, BCPS,
More information